The Cigna Group (CI) — Company Research

Last Updated: 12 November 2026

The Cigna Group is a US health services company built around two businesses: Evernorth Health Services, which runs the Express Scripts pharmacy benefit manager and the Accredo specialty pharmacy, and Cigna Healthcare, which provides medical, dental and behavioural benefits mainly to employers. With FY2025 revenue of $274.9bn it is one of the largest companies in the US by sales. The business is in the middle of a shift to a rebate-free pharmacy benefit model and a leadership change, with Brian Evanko CEO since 01 Jul 2026. This report covers the latest filings, including Q3 2026 results released on 05 Nov 2026. Track the shares on our Live Charts, check market-moving events on the Economic Calendar, and join the discussion in the ChartsView Forum.

1. Company Snapshot

2. Bull Case vs Bear Case

Bull Case

• Specialty pharmacy momentum: Specialty and Care Services pre-tax income rose 15% in Q3 2026 to $1,064m as more patients moved to lower-cost biosimilars and specialty generics.
• Guidance keeps rising: 2026 adjusted EPS guidance has been raised every quarter, from at least $30.25 in February to at least $30.60 on 05 Nov 2026.
• Long-range targets: At the 30 Sep 2026 Investor Day management set 10% to 14% adjusted EPS compound growth and about $50bn of cumulative operating cash flow through 2030.
• Cigna Healthcare margins: Q3 2026 Cigna Healthcare pre-tax income rose 15% to $1,193m with a medical care ratio of 85.0%, and medical customers grew 2% year to date.

Bear Case

• PBM profit squeeze: Pharmacy Benefit Services pre-tax income fell 22% in Q3 2026 to $765m, and management has called 2027 a trough year for parts of that business.
• Rebate-free transition risk: Moving clients to an upfront-discount, fee-based model by 2028 changes how Express Scripts earns money, and the 10-K says it will weigh on near-term Evernorth earnings.
• Regulatory pressure on PBMs: The FTC settlement, Medicare Part D delinking in the Consolidated Appropriations Act 2026, a new Labor Department disclosure rule and state laws on PBM-owned pharmacies all constrain the model.
• Shrinking customer base: Total customer relationships fell 6% year to date to 177.6m, with pharmacy customers down 5% on expected client departures.

3. Segments & Revenue Mix

FY2025 adjusted revenues by segment, as a percentage of consolidated adjusted revenue of $274,651m. Shares add to more than 100% because of $8,139m of corporate eliminations (mostly Evernorth services provided to Cigna Healthcare).

Cigna sold its Medicare Advantage, Part D, Medicare supplemental and CareAllies businesses to Health Care Service Corporation (HCSC), with the sale closing on 19 Mar 2025.

4. Business Model & Moat

How it makes money. Evernorth earns fees and spreads for managing prescription drug benefits and earns product margins dispensing specialty drugs through Accredo; it generated about 85% of FY2025 revenue but on thin margins. Cigna Healthcare collects premiums from fully insured customers and administrative fees from self-funded employers, earning the difference between premiums and medical costs (a medical care ratio of 84.4% in FY2025).

Scale as the moat. Express Scripts is one of the three largest US PBMs alongside CVS Caremark and Optum Rx. Purchasing scale with drugmakers and pharmacies, and contracts with its three largest clients renewed through the end of the decade, are hard for smaller rivals to match.

Rebate-free model. Announced on 27 Oct 2025, the new model passes drugmaker discounts to patients at the counter, pays pharmacies on a cost-plus basis, and replaces rebate guarantees with a stated administrative fee. Cigna Healthcare's fully insured plans adopt it from 2027, and it becomes Evernorth's standard offering ("Signature") from 2028.

Capital allocation. Cigna paid $1,236m of dividends in the first nine months of 2026, has repurchased about $500m of stock in 2026 (versus $3.6bn in 2025), and targets about 40% debt-to-capital by end-2026 (41.8% at 30 Sep 2026).

5. Financial Health

Annual figures from Cigna's 10-K filings, SEC XBRL data and Q4 earnings releases.

† FY2022 adjusted EPS recast to $23.36 (from $23.27) and GAAP EPS shown as recast for the 2023 change in insurance contract accounting; FY2021 GAAP EPS is the recast $15.75 ($15.73 as first reported). FY2024 GAAP EPS includes a $9.53 per share non-cash investment loss. Adjusted EPS is adjusted income from operations per share. Long-term debt excludes the current portion ($592m short-term debt at end-2025).

Quarterly results, most recent first.

Q3 2026 GAAP EPS fell year on year because Q3 2025 included a $241m after-tax gain on a business sale. Q2 2026 growth is computed from reported revenue.

Cash flow and balance sheet. FY2025 operating cash flow was $9,601m, capex (property and equipment purchases, net) $1,212m, and depreciation and amortisation $2,775m. Nine-month 2026 operating cash flow was $3,281m against company guidance of about $9.0bn for the full year. At 30 Sep 2026 total debt was $31,142m ($2,293m short-term including $500m of commercial paper, plus $28,849m long-term), against cash of $6,186m and short-term investments of $1,109m. In Sep 2025 Cigna issued $4.5bn of senior notes, partly to repay a $2.0bn term loan used for the $3.5bn Shields Health Solutions investment.

6. Valuation Snapshot

Raw metrics, November 2026. Not opinions on whether the stock is cheap or expensive.

7. What Are They Building

• "Lead to One" strategy: Presented at the 30 Sep 2026 Investor Day, it centres on leadership in complex care, alongside "Accelerate to One", a $3bn multi-year programme covering process modernisation, AI-enabled tools for staff and vendor discipline.
• Rebate-free pharmacy benefits: Express Scripts is moving clients to upfront point-of-sale discounts, cost-plus pharmacy pay and a flat administrative fee, standard from 2028 under the "Signature" name.
• Biosimilars through Quallent: Evernorth has offered a Humira biosimilar at $0 out of pocket since 2024 and a Stelara biosimilar at $0 through Accredo from 2025, each priced more than 80% below the brand's list price.
• GLP-1 programmes: EncircleRx offers employers a cost cap or savings guarantee on GLP-1 spend with lifestyle partners, EnGuide Pharmacy supports GLP-1 patients, and a $200 a month member cap applies to key GLP-1 drugs.
• Health Sense: Announced 06 Oct 2026, a personalised guidance and clinical support model rolling out from early 2027, first for oncology and cardiometabolic patients.
• Portfolio moves: a $3.5bn preferred-stock investment in Shields Health Solutions (Sep 2025), an exit from ACA individual plans from 01 Jan 2027 (about 369,000 lives in 11 states), and a strategic review of eviCore announced 30 Apr 2026.

8. Competitive Landscape

In pharmacy benefits Express Scripts competes mainly with CVS Caremark and UnitedHealth's Optum Rx. CVS announced on 04 Nov 2026 that it will separate its retail pharmacy from its PBM and insurance businesses.

9. Insider Activity

Brian Evanko became CEO on 01 Jul 2026, succeeding David Cordani, who remains Executive Chair. The table lists 2026 Form 4 open-market and option-linked sales; there were no open-market purchases by insiders in 2026.

Source: SEC Form 4 filings for CIK 1739940. Grants, phantom units and tax withholding are excluded. The Q3 2026 10-Q states no director or officer adopted, changed or ended a 10b5-1 plan in the quarter.

10. Key Risks

• PBM regulation: Medicare Part D delinking under the Consolidated Appropriations Act 2026, the Labor Department's PBM disclosure rule (plan years from 01 Jul 2027), state limits on PBM-owned pharmacies such as Tennessee's, and the FTC order with a three-year monitor all narrow how Express Scripts can earn money.
• Business model transition: The rebate-free model replaces rebate economics with fees; Pharmacy Benefit Services profit is already down sharply in 2026 and management expects 2027 to be a trough year for part of it.
• Client concentration: Large renewals with the top three clients run to the end of the decade at renewal pricing, and pharmacy customers are down 5% year to date.
• Litigation: Antitrust and underpayment suits from pharmacies and other claims led to $126m of pre-tax litigation charges in the first nine months of 2026.
• Drug trend and pipeline: Slower GLP-1 volumes, employers dropping weight-loss coverage and a maturing biosimilar wave (Humira, Stelara, Revlimid) could slow Specialty and Care growth.
• Medical costs: A rise in medical cost trend or stop-loss claims would push the medical care ratio (85.0% in Q3 2026) above guidance of 84.2% plus or minus 25bp.
• Leverage and investments: $31.1bn of debt, 41.8% debt-to-capital, and a history of strategic write-downs (VillageMD in 2024) add risk to the $3.5bn Shields investment and the $3bn modernisation programme.

11. Recent Developments

• 10 Nov 2026 — UBS healthcare conference. Management reaffirmed its 2030 targets, described 2027 as a trough year for part of Pharmacy Benefit Services and said it targets about 40% leverage by end-2026 (per conference coverage).
• 05 Nov 2026 — Q3 results beat, outlook raised. Revenue rose 6% to $73,683m and adjusted EPS rose to $7.98 from $7.83; 2026 adjusted EPS guidance was raised to at least $30.60.
• 04 Nov 2026 — CVS to split. Rival CVS Health said it will separate its retail pharmacy from its PBM and insurance businesses.
• 29 Oct 2026 — PBM disclosure rule. The Labor Department finalised a rule requiring PBMs to disclose compensation to large self-insured employer plans, effective for plan years from 01 Jul 2027.
• 28 Oct 2026 — Dividend declared. The board declared a $1.56 quarterly dividend payable 17 Dec 2026.
• 06 Oct 2026 — Health Sense launched. Cigna Healthcare introduced a personalised guidance and clinical support model rolling out from early 2027.
• 30 Sep 2026 — Investor Day. Cigna set out "Lead to One", 2030 targets of 10% to 14% adjusted EPS growth and about $50bn of operating cash flow, and a $3bn modernisation programme.

12. Key Dates

• 24 Nov 2026 — Next FINRA short-interest release.
• 03 Dec 2026 — Record and ex-dividend date for the $1.56 quarterly dividend.
• 17 Dec 2026 — Quarterly dividend payment.
• 01 Jan 2027 — Exit from ACA individual plans takes effect; Cigna Healthcare fully insured plans move to the rebate-free pharmacy model.
• Expected Feb 2027 — Q4 and FY2026 results with full 2027 guidance; date not yet confirmed (FY2025 results were released 05 Feb 2026).
• 01 Jul 2027 — Labor Department PBM disclosure rule applies to plan years beginning on or after this date.
• Expected Jan 2028 — Rebate-free "Signature" model becomes Evernorth's standard pharmacy benefit offering.

Tennessee's law on PBM-owned pharmacies, which Express Scripts is challenging in court, is due to take effect in July 2028.

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.